(0.01%) 5 479.00 points
(-0.01%) 38 814 points
(0.05%) 19 932 points
(0.26%) $80.54
(1.04%) $2.82
(0.12%) $2 331.90
(-0.33%) $29.30
(-0.03%) $970.60
(0.04%) $0.932
(-0.09%) $10.64
(0.09%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells...
Stats | |
---|---|
Šios dienos apimtis | 94 426 |
Vidutinė apimtis | 262 332 |
Rinkos kapitalizacija | 9.57M |
EPS | $-0.240 ( Q2 | 2023-08-10 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.225 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0390 (10.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-08-23 | Zabrowksi Dan | Sell | 100 000 | Stock Option (right to buy) |
2023-08-23 | Wertheimer Samuel P | Sell | 146 383 | Common Stock |
2023-08-23 | Wertheimer Samuel P | Sell | 100 000 | Stock Option (right to buy) |
2023-08-23 | Wertheimer Samuel P | Sell | 12 383 | Warrants (right to buy) |
2023-08-23 | Wertheimer Samuel P | Sell | 1 845 | Warrants (right to buy) |
INSIDER POWER |
---|
-62.55 |
Last 97 transactions |
Buy: 2 466 920 | Sell: 6 182 886 |
Tūris Koreliacija
Apexigen, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Apexigen, Inc. Koreliacija - Valiuta/Žaliavos
Apexigen, Inc. Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-1.590 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-1.590 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.931 |
FY | 2020 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-3.36 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Apexigen, Inc.
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.